0001104659-22-007970.txt : 20220127 0001104659-22-007970.hdr.sgml : 20220127 20220127060527 ACCESSION NUMBER: 0001104659-22-007970 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220127 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220127 DATE AS OF CHANGE: 20220127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 22559764 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm224623d1_8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 27, 2022

APOLLO MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37392	95-4472349
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801

(Address of Principal Executive Offices, and Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

On January 27, 2021, Apollo Medical Holdings, Inc. (“ApolloMed”) issued a press release announcing its acquisition of 100% of the fully diluted capitalization of Orma Health, Inc. and Provider Growth Solutions LLC.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Apollo Medical Holdings, Inc. dated January 27, 2022.

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APOLLO MEDICAL HOLDINGS, INC.

Dated: January 27, 2022	By:	/s/ Brandon Sim
	Name:	Brandon Sim
	Title:	Co-Chief Executive Officer

EX-99.1 2 tm224623d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Apollo Medical Holdings, Inc. Announces Acquisition of Value-Based Care Technology Platform Orma

Health, Welcomes New Chief Analytics Officer and President of Provider Solutions

ALHAMBRA, Calif., January 27, 2022 /PRNewswire/ -- Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it has acquired 100% of the fully diluted capitalization of Orma Health, Inc., and Provider Growth Solutions LLC (together, “Orma Health”) in accordance with an agreement between ApolloMed, Orma Health and certain equity holders of Orma Health.

Founded in 2020, Orma Health has helped many physician groups transition to and succeed in the delivery of value-based care, enabling them to focus on their passion—caring for patients. Orma Health’s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (“RPM”), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health’s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to help manage patients’ health. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity (“DCE”) and over 2,500 patients in California, Nevada, Arizona and Texas through its RPM platform.

Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, “We are excited about integrating Orma Health’s business and technological capabilities with those of ApolloMed, tapping their leadership team’s experience in working with DCEs and helping risk-bearing provider groups in the delivery of value-based care as we augment our capabilities to support providers in various Centers for Medicare & Medicaid Services Innovation Models. We believe this acquisition will further differentiate ApolloMed’s technology platform and analytic capabilities while adding complementary lines of business to our operations that serve as business development opportunities.”

Through leveraging its proprietary technology platform and extensive value-based care experience, ApolloMed has historically demonstrated tremendous success participating in Centers for Medicare & Medicaid Services (“CMS”) Innovation Models. The acquisition of Orma Health serves to accelerate ApolloMed’s product roadmap in developing an end-to-end technology platform that enables providers to succeed in all CMS Innovation Models, including DCE. Orma Health’s real-time Clinical AI and RPM technologies will also be integrated into ApolloMed's existing solutions for its managed care populations and will further enhance ApolloMed’s technology and analytics offering to its 1.2 million Medicare Advantage, Managed Medicaid, Commercial, and ACA members nationwide. This will allow ApolloMed providers to receive an additional layer of real-time, actionable insights and continue delivering high-quality care to their patients, tailored to their membership populations. As ApolloMed looks to expand its membership and enter new geographies, there are significant business development opportunities in deepening Orma Health's relationships with existing RPM providers and patients and extending that to ApolloMed's managed care and CMS Innovation Model solutions and offerings.

As part of the acquisition, Neil Ahuja, co-founder and Chief Executive Officer of Orma Health, will join ApolloMed as President, Provider Solutions and spearhead continued efforts to enable physicians to transition to value-based care models successfully. Yubin Park, co-founder and Chief Technology Officer of Orma Health, will join ApolloMed as Chief Analytics Officer and lead the continued development and integration of Orma Health’s AI-driven provider enablement technology into ApolloMed’s technology platform.

Mr. Ahuja commented, “We are pleased to be joining ApolloMed, bringing Orma Health’s core competencies in developing innovative healthcare technologies that drive tangible outcomes for providers and their patients. ApolloMed has been a leading healthcare management company with a long history of successfully and profitably empowering physicians in the delivery of value-based care, making it the perfect partner for us. We look forward to contributing our expertise to expanding ApolloMed’s MSO capabilities and the potential future opportunities that lie ahead.”

Mr. Park added, “I am excited to begin working closely with the ApolloMed team on integrating Orma Health’s technologies with that of ApolloMed. At Orma Health, we, like ApolloMed, believe that data is king. The information we gather and analyze about our members over the years is critical to our ability to deliver the best healthcare experience and outcomes for patients. We are thrilled that Orma Health is now a part of ApolloMed’s worthy mission of empowering providers in delivering high-quality care and improved outcomes for its members.”

According to the terms of the agreement, a portion of the purchase price was paid in cash to the equity holders of Orma Health upon the closing of the transaction, another portion was paid in ApolloMed stock to the equity holders of Orma Health upon the closing of the transaction, and the remainder of the purchase price is to be paid in a combination of cash and stock to the equity holders contingent upon Orma Health achieving certain operational milestones over the 18 months after the closing. The Company will fund the transaction from cash on hand and shares of ApolloMed stock.

About Apollo Medical Holdings, Inc.

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and a Next Generation Accountable Care Organization (NGACO). For more information, please visit www.apollomed.net.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements included in this press release that are not a description of historical facts are forward-looking statements. Words and phrases such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or similar expressions are intended to identify forward-looking statements and are based on the Company’s current beliefs and expectations. These forward-looking statements include, without limitation, statements about the Company’s acquisition of and arrangements with Orma Health, integration of Orma Health into ApolloMed operations, benefits and synergies of the transaction, future opportunities for the combined businesses, ApolloMed’s ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth and expansion plans, and future collaboration opportunities, and any other statements regarding events or developments that the Company believes or anticipates will or may occur in the future. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of ApolloMed’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in ApolloMed’s reports filed with the Securities and Exchange Commission, including, without limitation, the risk factors contained in ApolloMed’s Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Reports on Form 10-Q.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

(626) 943-6491

investors@apollomed.net

Carolyne Sohn, The Equity Group

(415) 568-2255

csohn@equityny.com

EX-101.SCH 3 ameh-20220127.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20220127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ameh-20220127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_001.gif GRAPHIC begin 644 image_001.gif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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 27, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 27, 2022
Entity File Number	001-37392
Entity Registrant Name	APOLLO MEDICAL HOLDINGS, INC.
Entity Central Index Key	0001083446
Entity Tax Identification Number	95-4472349
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1668 S. Garfield Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91801
City Area Code	626
Local Phone Number	282-0288
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	AMEH
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 tm224623d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2022-01-27 2022-01-27 iso4217:USD shares iso4217:USD shares 0001083446 false 8-K 2022-01-27 APOLLO MEDICAL HOLDINGS, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock AMEH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports tm224623d1_8k.htm ameh-20220127.xsd ameh-20220127_lab.xml ameh-20220127_pre.xml tm224623d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm224623d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm224623d1_8k.htm" ] }, "labelLink": { "local": [ "ameh-20220127_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20220127_pre.xml" ] }, "schema": { "local": [ "ameh-20220127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20220127", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224623d1_8k.htm", "contextRef": "From2022-01-27to2022-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://apollomed.net/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224623d1_8k.htm", "contextRef": "From2022-01-27to2022-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-007970-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-007970-xbrl.zip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end